Globus Medical (GMED) Cash & Equivalents (2011 - 2026)

Globus Medical's Cash & Equivalents history runs 16 years deep, the most recent figure standing at $560.9 million for Q1 2026.

• Quarterly Cash & Equivalents rose 21.61% year-over-year to $560.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $560.9 million (up 21.61% YoY) and the FY2025 annual result came in at $526.2 million, down 32.93% from the prior year.
• Cash & Equivalents was $560.9 million for Q1 2026 at Globus Medical, up from $526.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $784.4 million in Q4 2024 and bottomed at $134.2 million in Q3 2022.
• A 5-year average of $368.1 million and a median of $354.1 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents slumped 62.91% — and 2023, when it jumped 210.56%.
• Globus Medical's Cash & Equivalents stood at $150.5 million in 2022, then soared by 210.56% to $467.3 million in 2023, then surged by 67.87% to $784.4 million in 2024, then slumped by 32.93% to $526.2 million in 2025, then rose by 6.61% to $560.9 million in 2026.
• Business Quant data shows GMED's Cash & Equivalents at $560.9 million in Q1 2026, $526.2 million in Q4 2025, and $371.8 million in Q3 2025.